L'intérêt à découvert pour Glaukos donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Glaukos. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Glaukos (NYSE:GKOS) Stock, Rapport sur les intérêts à découvert

Glaukos

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Glaukos Corp

In the preceding three months, 7 analysts have released ratings for Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Glaukos, revealing an average target of $170.86, a high estimate of $200.00, and a low estimate of $140.00. This upward trend is apparent, with the current average reflecting a 4.27% increase from the previous average price target of $163.86.
<img src="https://www.benzinga.com/files/images/story/2025/1744840876_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Glaukos. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Anthony Petrone &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $175.00&#x7C;$200.00 &#x7C; 
&#x7C;Matt O'Brien &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $165.00&#x7C;$180.00 &#x7C; 
&#x7C;Richard Newitter &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $140.00&#x7C;$185.00 &#x7C; 
&#x7C;Larry Biegelsen &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $160.00&#x7C;$153.00 &#x7C; 
&#x7C;David Saxon &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $176.00&#x7C;$149.00 &#x7C; 
&#x7C;Anthony Petrone &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $200.00&#x7C;$140.00 &#x7C; 
&#x7C;Matt O'Brien &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $180.00&#x7C;$140.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Glaukos. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Glaukos's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Glaukos analyst ratings.</a>
<h2>Discovering Glaukos: A Closer Look</h2>
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
<h3>Glaukos: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Glaukos showcased positive performance, achieving a revenue growth rate of 28.09% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Glaukos's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -31.83%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.68%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Glaukos's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.53%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.13, Glaukos adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

GKOS

Forecasting The Future: 7 Analyst Projections For Glaukos

Mizuho analyst Anthony Petrone maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Outperform and lowers the price target from $200 to $175.

News

Price Target

Mizuho Maintains Outperform on Glaukos, Lowers Price Target to $175

Piper Sandler analyst Matt O'Brien maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and lowers the price target from $180 to $165.

Piper Sandler Maintains Overweight on Glaukos, Lowers Price Target to $165

Truist Securities analyst Richard Newitter maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and lowers the price target from $185 to $140.

Truist Securities Maintains Buy on Glaukos, Lowers Price Target to $140

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) has outperformed the market over the past 5 years by 10.4% on an annualized basis producing an average annual return of 27.01%. Currently, Glaukos has a market capitalization of $5.83 billion. 
Buying $1000 In GKOS: If an investor had bought $1000 of GKOS stock 5 years ago, it would be worth $3,057.55 today based on a price of $103.15 for GKOS at the time of writing.
<h3>Glaukos's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743200109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years

Inspire by RadiusXR is the only commercially available wearable vision diagnostic system that combines visual field testing correlated to the clinical standard with proven performance, onboard patient education, and data-driven intelligence to support more informed clinical decisions. Six ounces and purpose-built for future expansion, Inspire extends beyond traditional diagnostics to support testing for other chronic and systemic conditions.

Health Care

Contracts

General

Topcon Healthcare, RadiusXR, And Glaukos Announced A New Collaboration And The Launch Of RadiusXR's New Wearable Vision Testing Platform, Inspire

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) has outperformed the market over the past 5 years by 8.36% on an annualized basis producing an average annual return of 23.52%. Currently, Glaukos has a market capitalization of $6.95 billion. 
Buying $100 In GKOS: If an investor had bought $100 of GKOS stock 5 years ago, it would be worth $205.69 today based on a price of $126.07 for GKOS at the time of writing.
<h3>Glaukos's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740408314_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today

On Monday, Glaukos Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) received the &#8220;Day 74&#8221; notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-gen corneal cross-linking iLink therapy for keratoconus, a sight-threatening corneal disease, is sufficiently complete to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43908675/glaukos-announces-fda-acceptance-of-nda-submission-for-epioxa" rel="noreferrer noopener">permit a substantive review</a>.
The Prescription Drug User Fee Act goal date for the completion of the FDA&#8217;s review of the Epioxa NDA is set for Oct. 20, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43883818/glaukos-delivers-mixed-q4-results-analyst-sees-growing-investor-interest-during-transition" rel="noreferrer noopener">Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition</a>
&#8220;The acceptance of the Epioxa NDA represents another important step in being able to provide keratoconus patients and the ophthalmic community with the first FDA-approved, non-invasive corneal cross-linking drug therapy that does not require removal of the corneal epithelium, the outermost layer of the front of the eye,&#8221; said Glaukos CEO Thomas Burns.
The NDA submission includes data from two Phase 3 pivotal Epioxa trials, which achieved the pre-specified primary efficacy endpoints and demonstrated favorable tolerability and safety profiles.
Glaukos&#8217; corneal cross-linking iLink therapies use proprietary, bio-activated drug formulations designed to strengthen corneal tissue and halt the progression of keratoconus.
Glaukos&#8217; first-generation iLink therapy, known as Photrexa, or&nbsp;Epi-off, is the first and only FDA-approved therapy that has been shown to slow or halt disease progression.
Epioxa utilizes a proprietary, novel drug formulation designed to penetrate the epithelial layer of the cornea, a stronger UV-A irradiation protocol, and supplemental oxygen to enhance cross-linking.
Price Action: GKOS stock is up 25% at $157.36&nbsp;during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43890152/insulets-strong-q4-highlights-surging-omnipod-demand-and-growth-potential-analyst-sees-continued-growth-in-2025" target="_blank" rel="noreferrer noopener">Insulet&#8217;s Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst</a></li>
</ul>
Image: Shutterstock

Movers

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

The company has received the "Day 74" notification from the FDA acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a sight-threatening corneal disease, is sufficiently complete to permit a substantive review.&nbsp;

Glaukos Secures FDA Acceptance Of NDA Submission For Epioxa

All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about<a href="https://www.benzinga.com/25/02/43877634/us-stocks-fluctuate-in-preopen-volatility-doesnt-equal-financial-loss-unless-you-sell-says-expert"> the economic outlook.&nbsp;</a>
The University of Michigan consumer sentiment index fell to 64.7 in January, a decline of 10% and a steeper drop than expected. The 5-year inflation outlook in the survey is the highest since 1995 at 3.5% 
Existing home sales sank by 4.9% to a seasonally adjusted rate of 4.08 million in January, the sharpest decline in seven months, according to Trading Economics.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/02/43884153/us-services-drop-sharply-darkening-picture-of-high-prices-uncertainty-economist-says">US Services Drop Sharply: &#8216;Darkening Picture&#8217; Of High Prices, Uncertainty, Economist Says</a>
February's flash S&amp;P Global PMIs released <a href="https://www.benzinga.com/general/market-summary/25/02/43884153/us-services-drop-sharply-darkening-picture-of-high-prices-uncertainty-economist-says">Friday morning </a>revealed a sharp, unexpected drop in services and raised concerns about the health of the private sector.&nbsp;
"The upbeat mood seen among US businesses at the start of the year has evaporated, replaced with a darkening picture of heightened uncertainty, stalling business activity and rising prices," said Chris Williamson, chief business economist at S&amp;P Global Market Intelligence.&nbsp;
Natural gas futures rose another 4.5% Friday to $4.3/MMBtu, hitting a 25-month high as cold weather increased heating demand and disrupted production. The United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>), tracking the daily price movements of natural gas futures contracts, climbed 3.2%.&nbsp;
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was volatile as crypto markets reacted to a $1.4 billion Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) hack targeting Bybit&#8217;s cold wallet, <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43886224/bybit-founder-confirms-1-4-billion-ethereum-hack-blames-masked-transaction">one of the largest</a> security breaches in recent history.
<h2 class="wp-block-heading">Friday's Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,753.44</td>
<td>-1.05%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,069.73</td>
<td>-0.78%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,739.57</td>
<td>-0.99%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,231.48</td>
<td>-1.34%</td>
</tr>
</tbody>
</table>
</figure>
<h2 class="wp-block-heading">Friday's Stock Movers:&nbsp;</h2>
Shares of UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) slumped nearly 9% after the Wall Street Journal reported the Department of Justice launched an investigation into the company&#8217;s Medicare billing practices.
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Solaris Energy Infrastructure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) </li>
<li>Iamgold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) </li>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) </li>
<li>Glaukos Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) </li>
<li>MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) </li>
<li>The RealReal, Inc. (NASADQ:REAL) </li>
<li>Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>)</li>
<li>Globant S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) </li>
<li>Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) </li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) </li>
</ul>
Companies reporting on Monday included:&nbsp;
<ul>
<li>Domino&#8217;s Pizza Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) </li>
<li>Zoom Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) </li>
<li>Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) </li>
<li>Kosmos Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) </li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) </li>
<li>Hovnanian Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOV#NYSE">HOV</a>) </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43836832/trump-administration-orders-sweeping-pentagon-cuts-defense-sector-stocks-on-watch"> Trump Administration Orders Sweeping Pentagon Cuts: Palantir, Lockheed Martin, General Dynamics Among Stocks On Watch</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Market Summary

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

Real Estate

$BTC

$ETH

CELH

FANG

GLOB

MELI

REAL

RIVN

SMMT

Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday?

On Thursday, Glaukos Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>)&nbsp;reported fourth-quarter sales of $105.5 million, up 28% year over year and beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $100.49 million</a>.
The eye-focused company reported an adjusted EPS loss of 40 cents, narrowing from a 60-cent loss but missing the consensus <a href="https://www.benzinga.com/pressreleases/25/02/b43865644/glaukos-announces-fourth-quarter-and-full-year-2024-financial-results">estimate of a 38-cent loss.</a>
The gross margin for the fourth quarter of 2024 was approximately 73%, compared to approximately 77% in the same period in 2023. Non-GAAP gross margin for the fourth quarter of 2024 was approximately 82%, compared to 84% in the same period in 2023.
The company recorded an operating loss of $28.7 million, compared to an operating loss of $38.6 million a year ago. Adjusted loss from operations in the fourth quarter of 2024 was $18.3 million, compared to an operating loss of $32.4 million in the fourth quarter of 2023.
Glaucoma products recorded net sales of $84.1 million, up 30% year-over-year.
"Our record fourth-quarter results cap off a successful year of global execution of our key commercial and development plans, leaving us well positioned to continue to drive the strong momentum in our business this year and beyond," said Thomas Burns, Glaukos Chairman and CEO.
Also Read: <a href="https://www.benzinga.com/markets/commodities/25/02/43881018/gold-rush-20-heres-how-to-play-the-new-bull-market">Gold Rush 2.0? Here&#8217;s How To Play The New Bull Market</a>
Guidance:&nbsp;Glaukos expects 2025 revenue of $475 million-$485 million versus the consensus of $480.97 million.
William Blair says Glaukos is in the early stages of a major transformation following strong iDose results and a positive 2025 outlook. Analyst Margaret Kaczor Andrew expects the company to hit key reimbursement and commercial milestones in the coming year, driving further growth through 2025.
Glaukos is shifting from a company focused on surgical Minimally invasive glaucoma surgery (MIGS) to a broader business that combines pharmaceuticals and medical devices for eye care.
This transition, along with the recent dip in stock price, could attract more investor interest. William Blair keeps the stock rated Outperform.
Price Action: GKOS stock was down 11.8% at $138.75 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43847808/lenovo-q3-earnings-20-revenue-jump-ai-pcs-and-smartphones-power-market-expansion" target="_blank" rel="noreferrer noopener">Lenovo Q3 Earnings: 20% Revenue Jump, AI PCs and Smartphones Power Market Expansion</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

Guidance

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $153 to $160.

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $160

WIIM

Glaukos shares are trading lower after the company reported Q4 Adj Eps miss.

Needham analyst David Saxon maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $149 to $176.

Needham Maintains Buy on Glaukos, Raises Price Target to $176

Glaukos Sees FY25 Revenue $475M-$485M

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.38) by 5.26 percent. This is a 36.51 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $105.500 million which beat the analyst consensus estimate of $100.491 million by 4.98 percent. This is a 28.09 percent increase over sales of $82.365 million the same period last year.

Earnings Beats

Earnings Misses

Glaukos Q4 2024 Adj. EPS $(0.40) Misses $(0.38) Estimate, Sales $105.500M Beat $100.491M Estimate

ACCO

AKAM

ALIT

ALRM

ARDX

ATHM

AXTI

BABA

BAND

BBDC

BBIO

BIGC

BILI

BIRK

BJRI

BKNG

BLDR

CARG

CCRD

CDRO

CENX

CERS

CGAU

COKE

COLD

CPRT

CRAI

CSTM

DAVA

DBRG

DGICA

DGICB

DINO

DVAX

EPAM

ESAB

EXPI

FIVN

FRPT

FYBR

GDYN

GLPI

GMED

GRAL

INDI

INDV

INOD

INSM

IRTC

ITGR

Earnings Scheduled For February 20, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keefe, Bruyette &amp; Woods analyst Meyer Shields upgraded The Travelers Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) from Market Perform to Outperform and raised the price target from $275 to $286. Travelers shares closed at $238.40 on Tuesday. <a href="https://www.benzinga.com/quote/TRV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Janardan Menon upgraded the rating for STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) from Hold to Buy. STMicroelectronics shares closed at $24.41 on Tuesday. <a href="https://www.benzinga.com/quote/STM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Wamsi Mohan upgraded NetApp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) from Underperform to Neutral and raised the price target from $121 to $128. NetApp shares closed at $120.52 on Tuesday. <a href="https://www.benzinga.com/quote/NTAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Anthony Petrone upgrades Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) from Neutral to Outperform and raised the price target from $140 to $200. Glaukos shares closed at $152.96 on Tuesday. <a href="https://www.benzinga.com/quote/GKOS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert upgraded the rating for CervoMed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) from Hold to Buy and announced a $10 price target. CervoMed shares closed at $2.23 on Tuesday. <a href="https://www.benzinga.com/quote/CRVO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NTAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="570" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19082610/image-166-1024x570.png" alt="" class="wp-image-788905" style="width:298px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19082610/image-166-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19082610/image-166-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19082610/image-166-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19082610/image-166.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Upgrades

Pre-Market Outlook

Markets

CRVO

NTAP

This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday

Mizuho analyst Anthony Petrone upgrades Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) from Neutral to Outperform and raises the price target from $140 to $200.

Mizuho Upgrades Glaukos to Outperform, Raises Price Target to $200

Glaukos's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) short percent of float has risen 4.05% since its last report. The company recently reported that it has 3.36 million shares sold short, which is 9.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Glaukos Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739379614_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Glaukos has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Glaukos's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Glaukos's peer group average for short interest as a percentage of float is 3.38%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Glaukos's Recent Short Interest

Press Releases

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Comments

Glaukos

Intérêt court

Glaukos (NYSE:GKOS) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL